Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Resistance news


From To
FDA approves new HIV treatment for patients who have limited treatment options

Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.

07 March 2018
Infectious diseases doctor sounds an international alarm about HIV treatment resistance in the Philippines

Dr. Edsel Salvana explains the global implications of treatment-resistant HIV in the Philippines.

25 January 2018
Science Speaks
AZT: The phoenix of HIV treatment

During the last 30 years, over 15 million people have received AZT: an antiretroviral used to prevent HIV/AIDS. While it has now been replaced with other drugs in high income countries, it is still used widely in low-to-middle-income countries; this poses issues due to difficulties in detecting resistance to the drug and the side effects it carries. In this blog, author of a paper published in Infectious Disease of Poverty, Eric J. Arts, discusses his career long connection to AZT and the issues with AZT-based treatments in sub-Saharan Africa.

24 January 2018
BMC Blogs Network (blog)
Immediate HIV Treatment Has Little Impact on Risk of Future Drug Resistance

Starting antiretroviral therapy (ART) immediately rather waiting until a person's CD4 count falls below 500 cells/µL has almost no impact on the person's risk of developing antiretroviral resistance over the next seven years, according to a study published online in the journal AIDS. In this 51,000-person analysis, the impact of immediate ART on acquired drug resistance disappeared almost completely among people starting treatment in 2005 or later.

07 January 2018
The Body Pro
Transition to dolutegravir cost-effective in LMICs with high HIV drug resistance

In low- and middle-income countries, resistance to non-nucleoside reverse transcriptase inhibitors, or NNRTIs, is nearing and exceeding 10% in patients with HIV who are initiating or reinitiating first-line ART, according to recent data. A new modeling study showed that transitioning first-line ART from NNRTIs to dolutegravir may be a cost-effective way to reverse this increasing trend in resistance.

13 December 2017
Rising levels of HIV drug resistance

HIV drug resistance is approaching and exceeding 10 percent in people living with HIV who are about to initiate or reinitiate first-line antiretroviral therapy, according to the largest meta-analysis to date on HIV drug resistance, led by researchers at UCL and the World Health Organization (WHO) and funded by the Bill & Melinda Gates Foundation and the WHO.

01 December 2017
Eurekalert Inf Dis
BASHH welcomes publication of position statement on doxycycline as post-exposure prophylaxis for sexually transmitted infections

The British Association for Sexual Health and HIV (BASHH) has welcomed the publication of a new joint BASHH and Public Health England (PHE) position statement on the use of doxycycline as post-exposure prophylaxis (PEP) for sexually transmitted infections (STIs). A conference presentation had suggested that use of PEP with doxycycline was associated with a halving of the rates of bacterial STIs in men who have sex with men (MSM), in an extension of the French IPERGAY trial. However caution is advised.

03 November 2017
Uganda: ARVs Stock-Out Sparks Fear of Mass Drug Resistance

Civil society organisations and people living with HIV/Aids have warned that almost a million Ugandans could develop resistance to first-line anti-retroviral therapy if nothing is done about the nation-wide stock-out of drugs.

01 November 2017
Antibody-Based HIV Tx Proves Durable

The monoclonal antibody HIV drug ibalizumab, designed for patients who've developed severe drug resistance, had long-lasting protection in the 24-week extension phase of a phase III trial, researchers reported here.

10 October 2017
MedPage Today
HIV drug resistance found in more than half of young children in Africa

Approximately 54% of young children with HIV surveyed in Africa had resistance to one or more antiretroviral drugs, according to recent data.

24 August 2017
← First12345...8Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.